β-catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma

Cancer Research

Volumn 73, Issue 10, 2013, Pages 3181-3189

  Xu, Chuan ^a   Xie, Dan ^b   Yu, Shi Cang ^a   Yang, Xiao Jun ^a   He, Li Ru ^b   Yang, Jing ^a   Ping, Yi Fang ^a   Wang, Bin ^a   Yang, Lang ^a   Xu, Sen Lin ^a   Cui, Wei ^a   Wang, Qing Liang ^a   Fu, Wen Juan ^a   Liu, Qing ^a   Qian, Cheng ^a   Cui, You Hong ^a   Rich, Jeremy N ^c   Kung, Hsiang Fu ^a   Zhang, Xia ^a   Bian, Xiu Wu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE 1 FAMILY MEMBER A1; BETA CATENIN; CD133 ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; SOMATOMEDIN C; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CELL RENEWAL; DISEASE ASSOCIATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ADENOCARCINOMA; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LUNG NEOPLASMS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SOXB1 TRANSCRIPTION FACTORS;

EID: 84877843381     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4403     Document Type: Article

References (50)

1. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Travis WD. Pathology of lung cancer. Clin Chest Med 2011;32:669-92.
3. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-14. (Pubitemid 351267301)
4. Hermann PC, Bhaskar S, Cioffi M, Heeschen C. Cancer stem cells in solid tumors. Semin Cancer Biol 2010;20:77-84.
5. Clevers H. The cancer stem cell: Premises, promises and challenges. Nat Med 2011;17:313-9.
6. Sneddon JB, Werb Z. Location, location, location: The cancer stem cell niche. Cell Stem Cell 2007;1:607-11. (Pubitemid 350215340)
7. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012;148: 259-72.
8. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, et al. Oct-4 expression maintained cancer stem-like properties in lung cancerderived CD133-positive cells. PLoS One 2008;3:e2637.
9. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010;70: 10433-44.
10. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
11. Babaie Y, Herwig R, Greber B, Brink TC, Wruck W, Groth D, et al. Analysis of Oct4-dependent transcriptional networks regulating selfrenewal and pluripotency in human embryonic stem cells. Stem Cells 2007;25:500-10. (Pubitemid 46232806)
12. Leslie H, Sobin CW, editor. TNM classification of malignant tumours. 6th ed. New York: John Wiley & Sons, Inc; 2002.
13. He LR, Zhao HY, Li BK, Zhang LJ, Liu MZ, Kung HF, et al. Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients. Ann Oncol 2010;21:1675-81.
14. Levina V, Marrangoni A, Wang T, Parikh S, Su Y, Herberman R, et al. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res 2010;70: 338-46.
15. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50. (Pubitemid 41528093)
16. Yao XH, Ping YF, Chen JH, Xu CP, Chen DL, Zhang R, et al. Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J Pathol 2008;215:369-76.
17. Zhang X, Edwards JP, Mosser DM. Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription. J Immunol 2006;177:1282-8. (Pubitemid 44036634)
18. Jung M, Peterson H, Chavez L, Kahlem P, Lehrach H, Vilo J, et al. A data integration approach to mapping OCT4 gene regulatory networks operative in embryonic stem cells and embryonal carcinoma cells. PLoS ONE 2010;5:e10709.
19. Li Y, Geng YJ. A potential role for insulin-like growth factor signaling in induction of pluripotent stem cell formation. Growth Horm IGF Res 2010;20:391-8.
20. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009;7:e1000121.
21. Huntly BJ, Gilliland DG. Cancer biology: Summing up cancer stem cells. Nature 2005;435:1169-70. (Pubitemid 40943069)
22. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-44. (Pubitemid 44623625)
23. Baserga R. The insulin receptor substrate-1: A biomarker for cancer? Exp Cell Res 2009;315:727-32.
24. Bendall SC, Stewart MH, Menendez P, George D, Vijayaragavan K, Werbowetski-Ogilvie T, et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature 2007;448:1015-21. (Pubitemid 47345578)
25. Gallagher EJ, LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology 2011;152:2546-51.
26. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92: 1472-89.
27. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-smallcell lung cancer: A comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010;28:2174-80.
28. Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, et al. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer 2012;118:2454-65.
29. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009;106:16281-6.
30. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009;7:330-8.
31. Li X, Wan L, Geng J, Wu CL, Bai X. Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J Thorac Oncol 2012;7:1235-45.
32. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 2010;70: 9937-48.
33. Tirino V, Camerlingo R, Franco R, Malanga D, Rocca La A, Viglietto G, et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 2009;36:446-53.
34. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008; 13:16-24. (Pubitemid 351206693)
35. Shelton JG, Steelman LS, White ER, McCubrey JA. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 2004;3:372-9. (Pubitemid 41359089)
36. Medyouf H, Gusscott S, Wang H, Tseng JC, Wai C, Nemirovsky O, et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med 2011;208:1809-22.
37. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and selfrenewal. Clin Cancer Res 2010;16:3113-20.
38. Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young RA, et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell 2008;3:132-5.
39. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004;10:55-63. (Pubitemid 38524699)
40. Watanabe S, Umehara H, Murayama K, Okabe M, Kimura T, Nakano T. Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells. Oncogene 2006;25: 2697-707.
41. Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 2004;279:5017-24. (Pubitemid 38199098)
42. Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 2009;115:58-71.
43. Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, et al. Synergy between an IGF-1R antibody and Raf/MEK/ ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1Rmediated growth in hematopoietic cells. Leukemia 2006;20:1254-60. (Pubitemid 43905829)
44. Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J, et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res 2011;13:R52.
45. Kelly KF, Ng DY, Jayakumaran G, Wood GA, Koide H, Doble BW. b-Catenin enhances Oct-4 activity and reinforces pluripotency through a TCF-independent mechanism. Cell Stem Cell 2011;8:214-27.
46. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
47. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 2006;38:431-40.
48. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000;24:372-6. (Pubitemid 30187435)
49. Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, et al. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem 2005;280:24731-7. (Pubitemid 40934562)
50. van den Berg DL, Snoek T, Mullin NP, Yates A, Bezstarosti K, Demmers J, et al. An Oct4-centered protein interaction network in embryonic stem cells. Cell Stem Cell 2010;6:369-81.